INDIСATORS OF THE LYMPHOCYTE SUBSETS AS EFFICICIENCY PREDICTORS OF THERAPY WITH INHIBITORS OF TNFα IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE

(IBD), who were for the first time treated with TNFα blocker (infliximab). Our aim was to determine prognostic informative value of the immunological parameters in order to assess the treatment efficiency. A comprehensive research included seventy children with IBD from 12 to 18 years old in the cou...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	S. V. Petrichuk, L. V. Miroshkina, E. L. Semikina, A. P. Toptygina, A. S. Potapov, E. G. Tsimbalova, T. V. Radygina
Formato:	article
Lenguaje:	RU
Publicado:	SPb RAACI 2018
Materias:	we have performed a study of blood lymphocyte subsets in children with inflammatory bowel disease Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/bd5236eb49264d118e8246728a9edef0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bd5236eb49264d118e8246728a9edef0
record_format	dspace
spelling	oai:doaj.org-article:bd5236eb49264d118e8246728a9edef02021-11-18T08:03:47ZINDIСATORS OF THE LYMPHOCYTE SUBSETS AS EFFICICIENCY PREDICTORS OF THERAPY WITH INHIBITORS OF TNFα IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE1563-06252313-741X10.15789/1563-0625-2018-5-721-730https://doaj.org/article/bd5236eb49264d118e8246728a9edef02018-11-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/1640https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741X(IBD), who were for the first time treated with TNFα blocker (infliximab). Our aim was to determine prognostic informative value of the immunological parameters in order to assess the treatment efficiency. A comprehensive research included seventy children with IBD from 12 to 18 years old in the course of specific treatment (49 children with CD, 21 children with UC).The comparison group consisted of fifty healthy children of similar age who were subjected to a similar detailed examination. The patients were divided into two groups, depending on their therapeutic response following 1 year of biological therapy: the first group showed a persistent positive effect of the drug, and the second group exhibited only unstable effects of the treatment. We determined the contents of major and small subpopulations of peripheral blood lymphocytes before the first administration of infliximab. Immunophenotyping was performed by multicolor flow cytometry (FC 500), using the CD45, CD3, CD4, CD8, CD19, CD16, CD56, HLA-DR, CD5, CD161, CD127, CD25, and CD294 markers.We have revealed that the content of B lymphocytes was significantly reduced in children with unstable effects of therapy. By contrast, the B lymphocyte levels in children with persistent positive therapeutic effect did not differ from the comparison group. Analysis of the composition of the B lymphocyte profile showed an imbalance in the B1-to-B2 cell ratio, with decreased of B1 cell counts in IBD patients against the comparison group. In addition, the patients with unstable therapeutic effect showed a significant decrease in B2 cell numbers compared with a group with persistent effect and comparison group. The numbers of NK cells in IBD patients were found to be reduced against the comparison group. Assessment of T lymphocytes subsets revealed a number of features in the patients with minimal therapeutic effects, i.e., an increased level of activated T helper cells (CD4+CD25+CD127high) and Th17 lymphocytes (CD3+CD4+CD161+), as compared to children with stable effect of treatment and to the comparison group. Moreover, in children with minimal effects of therapy, the levels of Tregs within T-helper cell subsets were significantly higher than in the comparison group. By means of ROC analysis, we have identified most informative parameters for the groups with minimal versus persistent therapeutic effect, and showed a good quality for a discrimination model involving relative amount of Th17 cells, activated T helper cells and B lymphocytes. The number of Тh17 lymphocytes (% CD3+CD4+ lymphocytes) allowed to predict the effect of therapy with a TNFα blocker with high probability. The present study enables us to propose cellular immunity testing, as a promising tool for monitoring clinical state of IBD patients.S. V. PetrichukL. V. MiroshkinaE. L. SemikinaA. P. ToptyginaA. S. PotapovE. G. TsimbalovaT. V. RadyginaSPb RAACIarticlewe have performed a study of blood lymphocyte subsets in children with inflammatory bowel diseaseImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 20, Iss 5, Pp 721-730 (2018)
institution	DOAJ
collection	DOAJ
language	RU
topic	we have performed a study of blood lymphocyte subsets in children with inflammatory bowel disease Immunologic diseases. Allergy RC581-607
spellingShingle	we have performed a study of blood lymphocyte subsets in children with inflammatory bowel disease Immunologic diseases. Allergy RC581-607 S. V. Petrichuk L. V. Miroshkina E. L. Semikina A. P. Toptygina A. S. Potapov E. G. Tsimbalova T. V. Radygina INDIСATORS OF THE LYMPHOCYTE SUBSETS AS EFFICICIENCY PREDICTORS OF THERAPY WITH INHIBITORS OF TNFα IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE
description	(IBD), who were for the first time treated with TNFα blocker (infliximab). Our aim was to determine prognostic informative value of the immunological parameters in order to assess the treatment efficiency. A comprehensive research included seventy children with IBD from 12 to 18 years old in the course of specific treatment (49 children with CD, 21 children with UC).The comparison group consisted of fifty healthy children of similar age who were subjected to a similar detailed examination. The patients were divided into two groups, depending on their therapeutic response following 1 year of biological therapy: the first group showed a persistent positive effect of the drug, and the second group exhibited only unstable effects of the treatment. We determined the contents of major and small subpopulations of peripheral blood lymphocytes before the first administration of infliximab. Immunophenotyping was performed by multicolor flow cytometry (FC 500), using the CD45, CD3, CD4, CD8, CD19, CD16, CD56, HLA-DR, CD5, CD161, CD127, CD25, and CD294 markers.We have revealed that the content of B lymphocytes was significantly reduced in children with unstable effects of therapy. By contrast, the B lymphocyte levels in children with persistent positive therapeutic effect did not differ from the comparison group. Analysis of the composition of the B lymphocyte profile showed an imbalance in the B1-to-B2 cell ratio, with decreased of B1 cell counts in IBD patients against the comparison group. In addition, the patients with unstable therapeutic effect showed a significant decrease in B2 cell numbers compared with a group with persistent effect and comparison group. The numbers of NK cells in IBD patients were found to be reduced against the comparison group. Assessment of T lymphocytes subsets revealed a number of features in the patients with minimal therapeutic effects, i.e., an increased level of activated T helper cells (CD4+CD25+CD127high) and Th17 lymphocytes (CD3+CD4+CD161+), as compared to children with stable effect of treatment and to the comparison group. Moreover, in children with minimal effects of therapy, the levels of Tregs within T-helper cell subsets were significantly higher than in the comparison group. By means of ROC analysis, we have identified most informative parameters for the groups with minimal versus persistent therapeutic effect, and showed a good quality for a discrimination model involving relative amount of Th17 cells, activated T helper cells and B lymphocytes. The number of Тh17 lymphocytes (% CD3+CD4+ lymphocytes) allowed to predict the effect of therapy with a TNFα blocker with high probability. The present study enables us to propose cellular immunity testing, as a promising tool for monitoring clinical state of IBD patients.
format	article
author	S. V. Petrichuk L. V. Miroshkina E. L. Semikina A. P. Toptygina A. S. Potapov E. G. Tsimbalova T. V. Radygina
author_facet	S. V. Petrichuk L. V. Miroshkina E. L. Semikina A. P. Toptygina A. S. Potapov E. G. Tsimbalova T. V. Radygina
author_sort	S. V. Petrichuk
title	INDIСATORS OF THE LYMPHOCYTE SUBSETS AS EFFICICIENCY PREDICTORS OF THERAPY WITH INHIBITORS OF TNFα IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE
title_short	INDIСATORS OF THE LYMPHOCYTE SUBSETS AS EFFICICIENCY PREDICTORS OF THERAPY WITH INHIBITORS OF TNFα IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE
title_full	INDIСATORS OF THE LYMPHOCYTE SUBSETS AS EFFICICIENCY PREDICTORS OF THERAPY WITH INHIBITORS OF TNFα IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE
title_fullStr	INDIСATORS OF THE LYMPHOCYTE SUBSETS AS EFFICICIENCY PREDICTORS OF THERAPY WITH INHIBITORS OF TNFα IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE
title_full_unstemmed	INDIСATORS OF THE LYMPHOCYTE SUBSETS AS EFFICICIENCY PREDICTORS OF THERAPY WITH INHIBITORS OF TNFα IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE
title_sort	indiсators of the lymphocyte subsets as efficiciency predictors of therapy with inhibitors of tnfα in children with inflammatory bowel disease
publisher	SPb RAACI
publishDate	2018
url	https://doaj.org/article/bd5236eb49264d118e8246728a9edef0
work_keys_str_mv	AT svpetrichuk indisatorsofthelymphocytesubsetsasefficiciencypredictorsoftherapywithinhibitorsoftnfainchildrenwithinflammatoryboweldisease AT lvmiroshkina indisatorsofthelymphocytesubsetsasefficiciencypredictorsoftherapywithinhibitorsoftnfainchildrenwithinflammatoryboweldisease AT elsemikina indisatorsofthelymphocytesubsetsasefficiciencypredictorsoftherapywithinhibitorsoftnfainchildrenwithinflammatoryboweldisease AT aptoptygina indisatorsofthelymphocytesubsetsasefficiciencypredictorsoftherapywithinhibitorsoftnfainchildrenwithinflammatoryboweldisease AT aspotapov indisatorsofthelymphocytesubsetsasefficiciencypredictorsoftherapywithinhibitorsoftnfainchildrenwithinflammatoryboweldisease AT egtsimbalova indisatorsofthelymphocytesubsetsasefficiciencypredictorsoftherapywithinhibitorsoftnfainchildrenwithinflammatoryboweldisease AT tvradygina indisatorsofthelymphocytesubsetsasefficiciencypredictorsoftherapywithinhibitorsoftnfainchildrenwithinflammatoryboweldisease
_version_	1718422376896528384

INDIСATORS OF THE LYMPHOCYTE SUBSETS AS EFFICICIENCY PREDICTORS OF THERAPY WITH INHIBITORS OF TNFα IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE

Ejemplares similares